• Largest acquisition in history of Spanish biotechnology sector and largest operation to date for Caixa Capital Risc
• Holding 20% of the capital, Caixa Capital Risc is Sanifit’s biggest stakeholder and has supported company since 2006, participating in all financing rounds for a total investment of over €23M
B2 cohort (high dose added to anti-PD-1) of the PDC-LUNG-101 trial with PDC*lung01 therapeutic cancer vaccine candidate for non-small cell lung cancer has been opened and first patients were dosed
Led by Biomunex alongside Institut Curie and GTP Bioways, with a total budget of €5.6 million, BiXAb5 non-conventional T cell redirection project seeks to create breakthrough immunotherapy approach to cancer treatment based on bispecific antibodies
German-based startup attracts venture funding from leading European VC firms to address ‘Agitation/Aggression’ in Alzheimer’s disease
• Strong first closing confirms relevance of AFB’s unique early-stage investment strategy; aiming to create, develop and finance promising European life sciences startups in innovative therapeutics
• Since 2017, AFB’s €68M ($80M) first fund – Advent France Biotechnology Seed-Fund I – has successfully financed 15 startups in France, Spain, Belgium and Ireland
Venture capital firm Advent France Biotechnology led fundraising, alongside Crédit Mutuel Innovation and Pierre Fabre
Co-founded by AFB and leading cancer institutes Gustave Roussy and Institut Curie, startup will use funding to prepare essential preclinical work to identify first oncology program to develop
Les fonds apportés vont permettre à la nouvelle start-up de développer une approche thérapeutique innovante pour les patients atteints de maladies inflammatoires chroniques
